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OBJECTIVE—Hypertension in diabetes is characterized by abnormal sodium homeostasis,
suggesting a particular role of natriuretic peptide pathway. Natriuretic peptides can affect blood
pressure (BP) through their plasma concentrations, which are dependent on their receptor ac-
tivities. We thus assessed the association between nine NPR3 gene polymorphisms and BP levels
in patients with type 2 diabetes.
RESEARCHDESIGNANDMETHODS—Ninesinglenucleotidepolymorphisms(SNPs)
tagging the haplotype structure of the NPR3 gene were genotyped in the 3,126 French Non-
insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular
Events, and Ramipril (DIABHYCAR) trial participants. We then used a second population (Dia-
bete de type 2, Nephropathie et Genetique [DIAB2NEPHROGENE]/Survie, Diabete de type 2 et
Genetique [SURDIAGENE] study) of 2,452 patients for the purpose of replication. Finally, we
separatelyinvestigatedsubjectsselectedaccordingtotheirrs2270915SNPgenotypesfortheirBP
response to salt restriction.
RESULTS—In DIABHYCAR patients, three SNPs (rs6889608, rs1173773, and rs2270915)
weresigniﬁcantlyassociatedwithsystolicBP(SBP).Theeffectofthers2270915wasreplicatedin
the second step population: AA homozygotes had a lower SBP than G carriers (137.4 6 19.1 vs.
140.0 6 20.2 mmHg, P=0.004). The rs2270915 inﬂuenced the response of SBP to salt re-
duction, with AA homozygous patients showing greater reductions after restriction of salt intake
compared with G carriers: 220 mmHg (243 to 28) vs. 23( 220 to +7); P=0.006.
CONCLUSIONS—We foundaconsistentand signiﬁcant association betweenthers2270915
polymorphism of the NPR3 gene and SBP in diabetic patients. This genetic variation may affect
pressure response to changes in dietary sodium.
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H
ypertension and type 2 diabetes are
two chronic conditions associated
epidemiologicallyandpathophysio-
logically. Hypertension is a well-known
risk factor for diabetic vascular complica-
tionsintype1diabetesandtype2diabetes,
and is a complex trait with an established
heritability (1). Genome-wide association
studies are complementary to a candidate
gene approach and have helped to iden-
tify new genetic pathways involved in
blood pressure (BP). However, only a
few genetic associations have been clearly
identiﬁed and replicated to date, leaving
someimpetustosearchfornewcandidate
genes.
Diabetic patients differ from nondia-
betic patients by having an increase in
total body sodium (2,3), renal tubular so-
dium reabsorption, and an impaired abil-
ity to excrete a sodium load (4). These
factors suggest that natriuretic peptides
(NPs) may play a key role in the patho-
physiologyofhypertensioninthediabetic
population.
The NP system regulates BP and ﬂuid
homeostasis by modifying glomerular
ﬁltration rate (GFR) and sodium urinary
excretion.Thissystem consists ofafamily
of three peptidic hormones (A-type NP,
B-type NP [BNP], and C-type NP) that
interact with three receptors (NP receptor
A, NP receptor B, and NP clearance re-
ceptor[NPRC]).TheNPRCisencodedby
the NPR3 gene and is a determinant of NP
plasma concentration. Local expression
of NPRC is linked to NP activity in the
kidney (5,6). The intracellular domain
of NPRC modulates the contraction/
relaxation properties of smooth muscle
cells (5). Genetic variation in the NPR3
may therefore affect the activity of NP
through affecting plasma levels or NPRC-
mediated vascular effects. The NPR3 is lo-
cated on chromosome 5p14-p13. It spans
;70kbandcontainseightexonsandseven
introns. Within the general population, al-
lelic variants of the NPR3 gene have been
reported to be associated with hyperten-
sion (6–8).
This study aimed to assess the in-
ﬂuence of genetic polymorphisms within
NPR3 on BP in patients with type 2
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Pathophysiology/Complications
ORIGINAL ARTICLEdiabetes. We ﬁrst used a candidate gene
approach in two independent large popu-
lations. We then completed our investiga-
tion with a sodium restriction functional
study.
RESEARCH DESIGN AND
METHODS
Study protocols and subjects
First-step population: DIABHYCAR study.
The design and results of the Non-
insulin-dependent DIABetes, HYperten-
sion, microalbuminuria or proteinuria,
CARdiovascular events, and ramipril
(DIABHYCAR) study have been reported
(9). Brieﬂy, the DIABHYCAR study is
a clinical trial comparing the effect of a
low dose of ramipril with placebo on car-
diovascular and renal complications of
patients with type 2 diabetes with micro-
or macroalbuminuria. The main selection
criteria were as follows: patients with type
2 diabetes undergoing treatment with oral
antidiabetic drugs, high urinary albumin
excretion, age $50 years, and serum cre-
atinine #150 mmol/L. This ﬁrst step pop-
ulation included 3,413 patients recruited
in France. From the ﬁrst step cohort data,
weselectedthesinglenucleotidepolymor-
phisms (SNPs) that were most signiﬁ-
cantly associated with differences in
systolic BP (SBP).
Second-step population: DIAB-2-
NEPHRO-GENE and SURDIAGENE
studies. This cohort, dedicated to repli-
cation, was previously described (10).
Brieﬂy, patients were recruited for the
D I A B e t ed et y p e2 ,N E P H R O p a t h i ee t
GENEtique (DIAB2-NEPHRO-GENE;
D2NG) or the SURvie, DIAbete de type
2 et GENEtique (SURDIAGENE; SDG)
study. The D2NG is a French multicenter
case-control study of patients with type 2
diabetes, designed to assess the genetic
determinants of diabetic nephropathy in
type 2 diabetes. The SDG study is an in-
ception cohort with ongoing recruitment
of patients with type 2 diabetes regularly
attending the diabetes department at
PoitiersUniversityHospital,France.Alto-
gether, the second step population com-
prised 2,635 unrelated patients (10). The
design of these studies was approved by
University Hospital Ethics Committees
(Angers and Poitiers, respectively). All
participants in the study gave their writ-
ten informed consent.
Sodium restriction functional study
As u b s e to fS D Gm i c r o -a n dm a c r o -
albuminuric patients selected for their
rs2270915 genotypes were invited to par-
ticipate in a “sodium-restriction func-
tional” study (study design detailed in
Supplementary Data and Supplementary
Fig. 1). We included seven AA-genotype
and seven AG- or GG-genotype patients,
matched for age (65 years), urinary albu-
min status (micro- or macroalbuminuria),
and antihypertensive therapy: renin-
angiotensin-aldosterone system blocker
use (angiotensin receptor blocker or ACE
inhibitor), and diuretics. Exclusion crite-
ria included uncontrolled hypertension,
estimated GFR ,30 mL/min (Modiﬁca-
tion of Diet in Renal Disease formula),
and prior low sodium diets. The study
design was approved by the Poitiers Uni-
versity Hospital Ethics Committee. All
patients gave informed consent before
starting the study.
Polymorphism determination
On the basis of the Caucasian European
population data available in the HapMap
phase II panel (http://www.hapmap.org),
at least one SNP was selected in each hap-
lotype block of this large gene, focusing
on SNPs associated with relevant end
points in the literature. Thus, we selected
one SNP (rs9716700) in the promoter re-
gion (6,7,11), three in haplotype block 1
(rs1421811,rs1252246,rs6889608)(11),
two in haplotype block 2 (rs700923,
rs16890196) (12), one in haplotype block
3 (rs1173773) (11), and two in haplotype
block4(rs1173743,rs2270915)(11,13,14)
(Supplementary Fig. 2).
The full set of nine SNPs was geno-
typed in the ﬁrst step cohort analysis.
SNPs were determined by quantitative
PCR performed using the Taqman method
(ABI/PRISM 7700; Applied Biosystems,
Foster City, CA) or allele-speciﬁcP C R -
based KASPar SNP genotyping system
(KBiosciences, Hoddesdon, U.K.).
T h et h r e eo ft h en i n eS N P sw i t h
nominalassociationwithSBPwereselected
for the replication step and determined
with the same methods. Genotyping er-
rors were checked on 96 randomly se-
lected samples with both TaqMan and
KASPAR methods with a 100% concor-
dance rate.
Laboratory methods
Serum creatinine and urinary albumin
were measured by nephelometry on a
Modular System P (Roche Diagnostics
GmbH, Mannheim, Germany). Renal
function was estimated by GFR using
the four-variable Modiﬁcation of Diet in
Renal Disease formula. Urinary creatinine
was measured on a Hitachi911 automatic
analyzer (Roche Diagnostics, Meylan,
France). Glycated hemoglobin (A1C) was
determined by using a high-performance
liquid chromatography method with an
ADAMS A1C HA-8160 analyzer (normal
values 4.0–6.0%; Menarini, Florence,
Italy). Plasma N-terminal pro B-type natri-
uretic peptide (NT-proBNP) concentration
was determined using ElecsysproBNP
sandwich immunoassay on a Modular
System E (Roche Diagnostics, Meylan,
France). Measures were duplicated on
each sample, and mean was considered
for statistical analyses.
Statistical analysis
Statistical analyses were performed with
StatView 5.0 (SAS Institute, Cary, NC).
Patient characteristics were expressed as
means 6 SD or medians (interquartile
range) for skewed distributions. Groups
were compared using the x
2 test for cate-
goricvariables orparametric(ANOVA)or
nonparametric (if not normally distrib-
uted, Kruskal-Wallis or Mann-Whitney
U tests) tests for continuous variables.
Allele frequencies were estimated by
the gene-counting method, and Hardy-
Weinberg equilibrium (HWE) was tested
bythex
2test.WeusedTHESIASsoftware
for pairwise linkage disequilibrium (LD)
between NPR3 polymorphisms (ex-
pressed in termsof the D’ and r
2 statistics)
and haplotype analysis (http://genecanvas.
ecgene.net/downloads.php?cat_id=1). As-
sociations between BP and genotypes
wereevaluatedbylinearregressionanalysis
and ANOVA.
Meta-analysis of our two cohorts was
performed using the METAL software
(http://www.sph.umich.edu/csg/abecasis/
Metal/index.html) based on the weighted
z score method.
The Bayesian method implemented
in BIMBAM (http://quartus.uchicago.
edu/~yguan/bimbam/index.html) was
used with the HapMap CEU data to im-
pute the genotype of other HapMap SNPs
in the NPR3 gene. The imputed SNPs
were subsequently subjected to associa-
tion testing with BP as well.
P values # 0.05 were considered sta-
tistically signiﬁcant.
RESULTS
First-step population: DIABHYCAR
study—univariate analysis
DNA samples were available from 3,126
French patients in the DIABHYCAR study.
Clinicalandbiologicalcharacteristicsofthe
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NPR3 polymorphisms and blood pressurepatients are presented in Supplementary
Table 1. Genotyping success ranged from
99.1 to 98.3%. The genotype distribution
was in HWE for all SNPs except for
rs6889608 (P=0.046) and rs1173743
(P=0.049). Pairwise LD is shown in
Supplementary Table 2.
Of the nine studied SNPs, three
(rs6889608, rs1173773, rs2270915) were
signiﬁcantly associated with SBP (Table 1)
and six were not (Supplementary Table 3).
AA homozygotes for the rs2270915 SNP
had an SBP of 143.9 6 13.0 vs. 144.9 6
13.6mmHgforGcarriers(P=0.03).Strat-
iﬁcation on presence or absence of obesity
(deﬁned as BMI .30 kg/m
2) showed an
association between SBP and rs1173773
in obese patients (P = 0.003) but not
in nonobese patients (Supplementary
Table 4).
Second-step population: D2NG and
SDG studies—univariate analysis
Baseline characteristics of replication
study participants are presented in
Supplementary Table 1. DNA samples
were available for 2,452 patients. Geno-
typing success ranged from 97.02 to
99.71%. There were 2,043 Europid and
409 non-Europid patients, including 88
subjects of African origin. We restricted
our analyses to Europid patients. In this
group, all the selected SNPs (rs6889608,
rs1173773, rs2270915) were in HWE.
SBP was signiﬁcantly associated with
rs2270915 but not with rs6889608 and
rs1173773 (Table 2). In agreement with
the DIABHYCAR study, AA homozygotes
for the rs2270915 SNP had a signiﬁcantly
lowerSBPthanGcarriers(137.4619.1vs.
140.0 6 20.2 mmHg, P=0.004). Stratiﬁ-
cation on obesity did not replicate in this
population (Supplementary Table 5).
Multivariate and conjunct analysis
Multiple linear regression analysis showed
that both rs1173773 and rs2270915, age,
and BMI were independent predictive fac-
tors of SBP in each cohort (Table 3).
In addition, we combined the geno-
type analysis for SBP in a meta-analysis of
ourtwocohorts,conﬁrmingthesigniﬁcant
association between SBP and rs2270915
(z score = 23.109, P = 0.002) but not
rs1173773 and rs6889608 (P =0 . 1 1 1
and 0.519, respectively).
The haplotype analysis on conjunct
cohorts evidenced that one haplotype
containingthe rs2270915Gallelewassig-
niﬁcantlyassociatedwithSBP(Supplementary
Table 6).
Sodium reduction study
No differences were observed regarding
duration of diabetes, medical history, or
baseline BP between rs2270915AA geno-
type and G-carrier participants.
The clinical and biological responses
to the sodium restriction functional study
are presented in Table 4. Urinary sodium
excretions did not differ between groups
at baseline or in response to sodium re-
striction.
SBP, urinary albumin excretion, and
NT-proBNP signiﬁcantly decreased un-
der restricted salt diet. The decrease was
moremarkedinAAthaninGcarriersfor
SBP and urinary albumin, suggesting a
signiﬁcant gene-environment interac-
tion. However, no such association was
found for NT-proBNP. The responses
to the salt restriction of SBP, accord-
ing to genotype group, are plotted in
Supplementary Fig. 3. The absolute dif-
ference in SBP after salt restriction was
220 mmHg (243 to 28) vs. 23( 220
to 7) (P=0.006) in AA versus G carriers,
respectively.
No signiﬁcant modiﬁcation of body
weight, heart rate, and serum creatinine
was observed in either of the two geno-
type groups (Supplementary Table 7).
CONCLUSIONS—We performed a
large-scale analysis of several genetic var-
iants within the NPR3 gene in more than
5,500 patients with type 2 diabetes. We
found that the rs2270915 SNP was asso-
ciated with differences in SBP in patients
with type 2 diabetes; in the DIABHYCAR
and D2NG/SDG studies, the G allele was
associated with a higher adjusted SBP of
1.1 and 1.7 mmHg, respectively. This G
allele was also present in a haplotype sig-
niﬁcantly associated with higher SBP. We
found that salt intake strongly inﬂuenced
the relationship between BP and this ge-
netic polymorphism, with a decreased
salt sensitivity in G carriers compared
with AA homozygotes.
The choice of the different SNPs was
based on the haplotype structure of the
NPR3, as detailed in RESEARCH DESIGN AND
METHODS. We tested the association be-
tween imputed genotypes and SBP in
the DIABHYCAR population. Graphically
this analysis further supported the choice
of SNPs rs6889608, rs1173773, and
rs2270915 (Supplementary Fig. 4).
All the studied SNPs were in HWE,
suggesting no selection bias in the repli-
cationstudyforwhichethnicbackground
was available. The current study mainly
found that the rs2270915 was associated
with SBP in the DIABHYCAR population,
with positive replication in the D2NG/
SDG studies. Other reports from the gen-
eral population were not in accordance
withourﬁndingintype2diabetes.Iemitsu
Table 1—Relationship between SBP and SNPs of NPR3 in patients from the DIABHYCAR study
SNP
Genotype
P value
codominant
model*/§ A1 carriers
P value A1
dominant
model† A2 carriers
P value A2
dominant
model‡ A1A1 A1A2 A2A2
rs6889608 CC CT TT C carriers T carriers
n =2 3 1 n =1 , 1 5 1 n =1 , 7 1 5 n =1 , 3 8 2 n =2 , 8 6 6
145.2 6 12.3 144.9 6 13.0 143.7 6 13.4 0.034/0.012 145.0 6 12.9 0.010 144.2 6 13.3 0.26
rs1173773 GG AG AA G carriers A carriers
n =3 3 2 n =1 , 3 9 7 n =1 , 3 6 9 n =1 , 7 2 9 n =2 , 7 6 6
142.4 6 13.2 144.4 6 13.5 144.7 6 12.9 0.018/0.019 144.1 6 13.5 0.16 144.5 6 13.2 0.005
rs2207915 GG AG AA G carriers A carriers
n =1 4 0 n = 987 n =1 , 9 7 1 n =1 , 1 2 7 n =2 , 9 5 8
145.8 6 13.9 144.8 6 13.5 143.9 6 13.0 0.08/0.024 144.9 6 13.6 0.035 144.2 6 13.2 0.17
Data are means 6 SD. */§ Upper P values correspond to ANOVAstatistics: A1A1 vs. A1A2 vs. A2A2./lower P values correspond to simple regression analysis: 0, 1, or 2
minor alleles. †A1 carriers vs. A2A2. ‡A2 carriers vs. A1A1.
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Saulnier and Associateset al. (14) found that the G allele was not
related to SBP in the general population.
TheseJapanesepatientshadasimilargeno-
type frequency as our patients, but only
291 nondiabetic subjects were studied
with a focus on arterial stiffness. Lanfear
et al. (13) did not ﬁnd a relationship be-
tweenthisSNPandBNPconcentrationson
the100genotypedCaucasianpatients.The
ﬁndings from Sarzani et al. (6), suggesting
thatthers9716700wasassociatedwithBP,
were not replicated. In our study, the
rs9716700 was in HWE, at variance with
the data from Sarzani et al. (6). Genotypic
frequencies were different in the two stud-
ies, suggesting different recruitments. We
also evidenced a relationship between SBP
and rs1173773 in obese patients (not re-
ported by Sarzani et al. [6]) but not for
rs9716700 as documented by others
(6,8). However, we focused on patients
with type 2 diabetes, who are well known
to be particularly salt sensitive (15), possi-
bly explaining the discrepancy for these
results.
T h ec o n j u n c ta n a l y s i ss h o w e dt h a ta
haplotype containing the rs2270915 G
allele was associated with an increased BP
compared with the reference haplotype.
In multivariate analysis, the rs2270915
dose effect had an impact on SBP ranging
from 1.1 to 1.7 mmHg in these two
different populations. This effect seems
to be modest, but it could be clinically
relevant. We can speculate from data of
clinical trials on BP that the rs2270915
effect on SBP could translate into a lower
cardiovascular mortality risk by 2.5%
over 4 years (16).
Our data from the functional salt
restriction study, although generated
on a small group, provide a better under-
standing of the effect of this genetic poly-
morphism on BP in patients with type 2
diabetes. We found that salt restriction
was associated with a decrease in SBP and
albuminuria, as demonstrated by others
(17). As previously reported, the salt-
sensitive AA genotype responded more
strongly to salt restriction on albumin ex-
cretion than the salt-resistant G carriers
(18). This result seems counterintuitive
because it is generally accepted that salt-
sensitivity is associated with hypertension
(19), and we found that salt-sensitive
patients (AA genotype) had a lower SBP
than salt-resistant patients (G carriers).
However, it has been reported that salt
supplementation downregulated NPRC
expression in the kidney (20). The gene
interaction found in the current study
therefore leads us to hypothesize that the
inﬂuence of NPR3 variants on BP could be
masked in the presence of high sodium
intake.
The speculations about the biological
impact of the rs2270915 SNP are excit-
ing. It is a nonsynonymous polymor-
phism resulting in the replacement of an
asparagine by an aspartate residue in the
COOH-terminal region of the NPRC,
N521D. In silico analysis using Poly-
Phen2 (http://genetics.bwh.harvard.edu/
pph2) predicted the consequence of this
rs2270915 to be “probably damaging” to
the protein. This residue is conserved in
various species, including humans, ro-
dents, and cows (21). This intracellular
truncated domain has afﬁnity for pertus-
sis toxin-sensitive G proteins and is able
to activate/inhibit various enzymes in the
cell,suchasadenylylcyclaseandisoforms
of phospholipase C (21,22). Synthetic
polypeptides generated by mutational
study of this 37-amino acid intracellu-
lar domain were used to identify the
homologous 17-amino acid sequence,
R
513RNHQEESN
521IGKHRELR
529,respon-
sible for these binding capacities (21) and
were necessary and sufﬁcient for the acti-
vation of G proteins and effector enzymes
(23). Recent studies suggest that changes
to this sequence, such as that introduced
by the missense mutation in the current
study, are likely to modify the tone of
smooth muscle cells, as suggested by re-
cent studies (23). NPRC is widely ex-
pressed in vascular smooth muscle cells
and mesangial cells (23,24). Changes
Table 2—Relationship between SBP and SNPs of NPR3 in Europid patients from the D2NG/SDG studies
SNP
Genotype
P value
codominant
model*/† A1 carriers
P value A1
dominant
model‡ A2 carriers
P value A2
dominant
model§ A1A1 A1A2 A2A2
rs6889608 CC CT TT C carriers T carriers
n =1 1 6 n = 685 n =1 , 1 6 0 n = 801 n =2 , 2 3 0
135.5 6 20.1 139.0 6 19.2 138.4 6 19.7 0.20/0.56 138.5 6 19.3 0.93 138.6 6 19.5 0.09
rs1173773 GG AG AA G carriers A carriers
n =2 3 4 n = 864 n =8 6 0 n =1 , 0 9 8 n =2 , 1 9 0
140.0 6 19.1 138.9 6 20.1 137.6 6 18.9 0.16/0.056 139.1 6 19.9 0.08 138.2 6 19.5 0.19
rs2207915 GG AG AA G carriers A carriers
n =9 1 n = 659 n =1 , 2 7 1 n = 750 n =2 , 4 4 0
137.0 6 19.8 140.4 6 20.2 137.4 6 19.1 0.004/0.031 140.0 6 20.2 0.004 138.4 6 19.5 0.48
Data are means 6 SD. */†Upper P values correspond to ANOVA statistics: A1A1 vs. A1A2 vs. A2A2./lower P values correspond to simple regression analysis: 0, 1, or 2
minor alleles. ‡A1 carriers vs. A2A2.§ A 2 carriers vs. A1A1.
Table 3—Impact of NPR3 genetic variants and clinical variables on SPB (mmHg)
from the DIABHYCAR and D2NG/SDG studies (multivariate analysis)
DIABHYCAR
P value
D2NG/SDG
P value Estimate 6 SE Estimate 6 SE
Sex (compared with male) 1.9 6 0.5 0.0004 21.5 6 0.9 0.1058
Age (for each increment of 1 year) 0.2 6 0.1 ,0.0001 0.3 6 0.04 ,0.0001
BMI (for each increment of 1 kg/m
2)0 . 3 6 0.1 ,0.0001 0.3 6 0.1 0.0003
rs6889608* 1.2 6 0.5 0.0087 20.5 6 0.7 0.5189
rs1173773* 20.9 6 0.4 0.0141 1.4 6 0.7 0.0296
rs2270915* 1.1 6 0.5 0.0163 1.7 6 0.8 0.0306
*For each addition of a minor allele (i.e., C, G, and G for rs6889608, rs1173773, rs2270915, respectively).
1202 DIABETES CARE, VOLUME 34, MAY 2011 care.diabetesjournals.org
NPR3 polymorphisms and blood pressurein the NPR3 primary sequence might
therefore affect systemic and renal hemo-
dynamics (natriuresis, vascular and me-
sangial tone) via at least two different
mechanisms: changes in NP clearance by
internalization and changes in the activa-
tion/inhibition capacities of the intracellu-
lar domain. Measuring atrial natriuretic
peptide response in kidney cells of pa-
tients with type 2 diabetes according to
rs2270915 genotype was beyond the
scope of this article.
Some limitations must be acknowl-
edged in this study. We had no infor-
mation regarding salt intake in the
DIABHYCAR and D2NG/SDG studies.
Salt intake may have affected the relation-
ship between BP and the genetic variants
of NPR3. Our functional study on salt re-
striction is exciting but must be regarded
as a pilot study. Although not performed
on patients with type 2 diabetes, ade-
quately powered studies on the genetic
component of salt sensitivity, such as
therecentlyreleasedDASHtrial,are man-
datory to replicate our ﬁndings (25).
Finally, the question of multiple test-
ing is an important issue. We found a
replicated effect of the rs2270915 SNP in
two independent cohorts. Associations
were of borderline signiﬁcation after Bon-
ferroni correction in the DIABHYCAR
population for any of the selected SNPs.
However, the LD between the SNPs sug-
gests that the tests were not indepen-
dent, and thus Bonferroni method may
overcorrect the multiplicity of testing. The
borderline P values nevertheless deserved
additional testing in a replication popula-
tion. In the D2NG/SDG study, the signif-
icant association of rs2270915 with SBP
was maintained after Bonferroni correc-
tion. The consistency of the results across
the studies, including the functional
study, strongly suggests that the associa-
tion is not a pure chance ﬁnding. Further
studies, particularly in patients from other
ethnic origins, are warranted.
The effect of this NPR3 variant ob-
served in two independent populations
was substantiated in a functional study.
Homozygous AA patients for the rs2270915
SNP could be identiﬁed as a low-risk ge-
notype and “salt restriction responders.”
Conversely, G carrier patients could be
classiﬁed as “high-risk” because they
seem to have higher SBP and are less sensi-
tivetosaltreduction.Ourdatasuggestinga
gene-environmentinteraction supportthe
speculation of an individual tailoring of
antihypertensive therapeutics according
to its NPR3 genotype. This point deserves
further conﬁrmation before routine clini-
cal use.
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Table 4—Clinical and biological response to salt reduction in the functional study
Variable Salt diet AA (n =7 ) P value
G carriers
(n =7 )
Genotype effect
(P value)
Global genotype
effect (P value)
UNa (mmol/24 h) Usual 215 6 91 232 6 85 0.749 0.51
Low 103 6 65 121 6 69 0.565
Treatment effect (P value) 0.018 0.018
Global treatment effect (P value) 0.001 0.949*
SBP (mmHg) Usual 144.6 6 14.3 137.4 6 7.7 0.338 0.51
Low 124.2 6 11.0 134.2 6 7.7 0.096
Treatment effect (P value) 0.018 0.40
Global treatment effect (P value) 0.006 0.006*
Ualb (mg/24 h) Usual 233 (419) 282 (405) 0.655 0.97
Low 178 (239) 239 (456) 0.655
Treatment effect (P value) 0.018 0.40
Global treatment effect (P value) 0.013 0.048*
NT-proBNP (pg/mL) Usual 97 (141) 147 (651) 0.338 0.07
Low 46 (149) 95 (181) 0.227
Treatment effect (P value) 0.128 0.0425
Global treatment effect (P value) 0.013 0.338*
Data are mean 6 SD or median (interquartile range). Treatment effect corresponds to the effect of the dietary salt restriction. UNa, urinary sodium excretion; Ualb,
urinary albumin excretion. *P values for estimated genotype-treatment interaction.
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